Hepatitis B and Hepatitis C Co-infection
Hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection is occurred generally in highly endemic areas and among persons with a high risk of parenteral infections, because of both virus have common routes of transmission. The worldwide prevalence of coinfection is unknown, but it is estimated to...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2015-09-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2015-20-03-120-127.pdf |
| _version_ | 1797915529410772992 |
|---|---|
| author | Bircan KAYAASLAN Gül Ruhsar YILMAZ |
| author_facet | Bircan KAYAASLAN Gül Ruhsar YILMAZ |
| author_sort | Bircan KAYAASLAN |
| collection | DOAJ |
| description | Hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection is occurred generally in highly endemic areas and among persons with a high risk of parenteral infections, because of both virus have common routes of transmission. The worldwide prevalence of coinfection is unknown, but it is estimated to be about 15 million HBV/HCV co-infected patients. HBV/HCV co-infection presents with a heterogeneous clinical appearance depending on the individual differences and diversity of the viral replication. HCV superinfection in patients with chronic HBV infection was the most common clinical features of coinfection in Asia-Pacific countries, while HBV superinfection was more common in Europe and United States. HBV/HCV interact with each other. HBV viral replication is generally suppressed by HCV. However, the longitudinal studies suggest that the viral interference is a fl uctuating dynamic process. Co-infection is characterized by a more severe liver injury and a higher incidence of cirrhosis and hepatocellular carcinoma (HCC). The dominant virus should be determined by pretreatment serological and virological evaluations. A good treatment response was obtained with pegile-interferon(Peg-IFN)/ribavirin in co-infected patients. Treatment outcomes was similar to HCV monoinfection. The effective treatment of HCV infection in the HBV/HCV co-infected patients may lead to HBV reactivation. For this reasons, long-term follow-up and monitoring for HBV infection are recommended in this patients. Although adding to a nucleos(t)ide analogues to the combination of Peg-IFN/ribavirin is a treatment alternative in HBV-active or dually-active co-infection, the optimal treatment strategies remains still unknown. The role of IFN-free direct
acting antivirals treatment in co-infection is another issue to be resolved. However, the treatment of HCV with new potent drugs without any anti-HBV effect may increase the risk of HBV reactivation. The introduction of new antiviral for the treatment of hepatitis C may alter the optimal treatment of HBV/HCV coinfection. Further studies are needed in this regard. |
| first_indexed | 2024-04-10T12:43:18Z |
| format | Article |
| id | doaj.art-aeea3d4e2f09460abdf45270944e68f4 |
| institution | Directory Open Access Journal |
| issn | 1300-932X 1300-932X |
| language | English |
| last_indexed | 2024-04-10T12:43:18Z |
| publishDate | 2015-09-01 |
| publisher | Bilimsel Tip Yayinevi |
| record_format | Article |
| series | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| spelling | doaj.art-aeea3d4e2f09460abdf45270944e68f42023-02-15T16:14:12ZengBilimsel Tip YayineviFlora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi1300-932X1300-932X2015-09-01203120127Hepatitis B and Hepatitis C Co-infectionBircan KAYAASLAN0Gül Ruhsar YILMAZ1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Yildirim Beyazit, Ankara, TurkeyClinic of Infectious Diseases and Clinical Microbiology, Ataturk Training and Research Hospital, Ankara, TurkeyHepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection is occurred generally in highly endemic areas and among persons with a high risk of parenteral infections, because of both virus have common routes of transmission. The worldwide prevalence of coinfection is unknown, but it is estimated to be about 15 million HBV/HCV co-infected patients. HBV/HCV co-infection presents with a heterogeneous clinical appearance depending on the individual differences and diversity of the viral replication. HCV superinfection in patients with chronic HBV infection was the most common clinical features of coinfection in Asia-Pacific countries, while HBV superinfection was more common in Europe and United States. HBV/HCV interact with each other. HBV viral replication is generally suppressed by HCV. However, the longitudinal studies suggest that the viral interference is a fl uctuating dynamic process. Co-infection is characterized by a more severe liver injury and a higher incidence of cirrhosis and hepatocellular carcinoma (HCC). The dominant virus should be determined by pretreatment serological and virological evaluations. A good treatment response was obtained with pegile-interferon(Peg-IFN)/ribavirin in co-infected patients. Treatment outcomes was similar to HCV monoinfection. The effective treatment of HCV infection in the HBV/HCV co-infected patients may lead to HBV reactivation. For this reasons, long-term follow-up and monitoring for HBV infection are recommended in this patients. Although adding to a nucleos(t)ide analogues to the combination of Peg-IFN/ribavirin is a treatment alternative in HBV-active or dually-active co-infection, the optimal treatment strategies remains still unknown. The role of IFN-free direct acting antivirals treatment in co-infection is another issue to be resolved. However, the treatment of HCV with new potent drugs without any anti-HBV effect may increase the risk of HBV reactivation. The introduction of new antiviral for the treatment of hepatitis C may alter the optimal treatment of HBV/HCV coinfection. Further studies are needed in this regard.http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2015-20-03-120-127.pdfHepatitis BHepatitis CCo-infection |
| spellingShingle | Bircan KAYAASLAN Gül Ruhsar YILMAZ Hepatitis B and Hepatitis C Co-infection Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi Hepatitis B Hepatitis C Co-infection |
| title | Hepatitis B and Hepatitis C Co-infection |
| title_full | Hepatitis B and Hepatitis C Co-infection |
| title_fullStr | Hepatitis B and Hepatitis C Co-infection |
| title_full_unstemmed | Hepatitis B and Hepatitis C Co-infection |
| title_short | Hepatitis B and Hepatitis C Co-infection |
| title_sort | hepatitis b and hepatitis c co infection |
| topic | Hepatitis B Hepatitis C Co-infection |
| url | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2015-20-03-120-127.pdf |
| work_keys_str_mv | AT bircankayaaslan hepatitisbandhepatitisccoinfection AT gulruhsaryilmaz hepatitisbandhepatitisccoinfection |